Facing international competition, talk about domes

In the face of international competition, talk about the domestic pharmaceutical packaging market

pharmaceutical packaging, as a very active branch in the field of packaging in China, its continuous renewal and progress have witnessed the rapid development of the packaging industry. After China's accession to the WTO, more international pharmaceutical enterprises began to enter China. On the one hand, this has intensified the competition in China's pharmaceutical industry, on the other hand, it has also improved the quality and technical level of the entire industry, which has become an inevitable trend to drive the development of pharmaceutical packaging. As the pharmaceutical industry is related to the life of ordinary people, 12. Tightening machine: imported from France taikangxi, which creates the particularity of pharmaceutical packaging. Therefore, in China, pharmaceutical packaging belongs to the scope of national food and drug administration. But from a technical point of view, the relationship between pharmaceutical packaging and packaging printing is very large, and paying attention to pharmaceutical packaging has become a reason! Based on this background, we interviewed Mr. Chen Qixiang, Secretary General of the packaging and Printing Committee of China Packaging Technology Association, and Mr. Ji Wei, director of Shanghai pharmaceutical packaging testing institute, to jointly interpret the domestic pharmaceutical packaging market

perspective on the current situation of pharmaceutical packaging

according to director Ji, at present, China's pharmaceutical enterprises are mainly distributed in Jiangsu, Zhejiang and Guangdong. In terms of quantity and scale, pharmaceutical enterprises in Guangdong and Jiangsu and Zhejiang are dominant. From the development of the past two years, the large-scale production of pharmaceutical enterprises is becoming more and more obvious, and the grade is also gradually improving. A development trend of modern pharmaceutical enterprises is that larger pharmaceutical factories are equipped with packaging enterprises themselves

at present, the extensive growth with high speed, low efficiency and high consumption is a typical feature of the development of pharmaceutical packaging in China. The packaging quality of most domestic pharmaceutical products is low, and there is still a large gap with developed countries. This can be proved by the following two data. At present, 65% of China's pharmaceutical packaging products are less than the level of the international developed countries in the 1980s, and the quality of packaging materials and the contribution rate of packaging to the pharmaceutical industry are low. In developed countries, pharmaceutical packaging accounts for 30% of the value of drugs, while the proportion in China is less than 10%. At present, for the domestic large-scale pharmaceutical packaging enterprises, there is little gap in equipment compared with foreign countries, but the software environment is very unsatisfactory

it is understood that the reasons for this gap are mainly concentrated in three aspects. First, the overall level of China's pharmaceutical industry is relatively low, and the technology of pharmaceutical production enterprises is relatively backward. From the perspective of the scale of pharmaceutical enterprises, China's pharmaceutical enterprises are many and small, the repeated production of drugs is serious, and the management level of pharmaceutical enterprises is low. Secondly, the relevant regulations and technical standards of China's pharmaceutical packaging industry are backward. At present, China has gradually launched the normative standard system of the pharmaceutical industry, but there is still a certain distance from the international standards. The lack of industry standard system leads to the situation that the packaging of pharmaceutical products is neither good nor bad. Finally, there are drawbacks in the drug circulation system. Pharmaceutical products have been mainly sold in hospitals for a long time, and the drugs sold in pharmacies account for only a small part of the total. This situation restricts the direct participation of drugs in market competition and restricts the development of pharmaceutical packaging

in addition, the current drug bidding system has seriously dampened the enthusiasm of pharmaceutical manufacturers. Enterprises cannot make great efforts to reform the packaging, and pharmaceutical packaging has remained old-fashioned for a long time. In addition, the backward technical level of pharmaceutical packaging machinery and materials and the weak quality awareness of practitioners are also factors restricting the development of pharmaceutical product packaging in China

the introduction of pharmaceutical packaging design standards

pharmaceutical packaging is a broad concept, and packaging design is a link that is easy to be ignored. According to director Ji, two factors should be considered in the design of pharmaceutical packaging, one is safety, the other is national characteristics. Compared with developed countries, there is still a certain distance in the level of pharmaceutical packaging design in China, such as the nonstandard use of drug names and batch numbers, the inconsistent use and quality standards of drug labels, the nonstandard use of terminology, the excessive packaging of drugs, and the lack of instructions, which do not reflect national characteristics in the design and are inconsistent with national culture and public aesthetic needs

with the improvement of people's consumption level and the introduction of new regulations and standards in related industries, the pharmaceutical product packaging industry has undergone a fundamental change. At present, almost all the top 100 global pharmaceutical enterprises have established joint ventures or wholly-owned pharmaceutical enterprises in China, which not only brings more new drug varieties, but also advanced pharmaceutical packaging concepts and standards

in order to adapt to this change, China's "Drug Administration Law" has added a chapter on "drug packaging and sub packaging", which makes special provisions on pharmaceutical packaging. Including: the name, specification, manufacturer, approval number, batch number, main ingredients, indications, usage, dosage, contraindications, adverse reactions and precautions of the drug must be indicated on the label or instruction manual of the drug package. The measures for the administration of materials and containers for pharmaceutical packaging (Provisional) (order 21) and the regulations on the administration of pharmaceutical packaging, labels and instructions (order 23) issued in 2000 also make detailed provisions on pharmaceutical packaging

according to Secretary General Chen, the regulations on the administration of pharmaceutical packaging, labels and instructions (Order No. 23) issued by the State Drug Administration not only standardized the standards of China's pharmaceutical packaging industry, but also unified the form of pharmaceutical packaging, which not only improved the requirements for hygiene and protective functions, but also emphasized the convenience and scientificity of use

in addition, the fierce market competition also puts forward higher requirements for the cost control of packaging. In the use of packaging materials, many composite materials have been widely used, strengthening the quality of packaging and improving the grade of drugs; The design and anti-counterfeiting of outer packaging containers have also been paid attention to by pharmaceutical enterprises

it is understood that in China's trademark registration system, voluntary registration is the main method, but compulsory registration is given to human drugs and tobacco products, because human drugs are related to the life, health and safety of ordinary people. In other words, drugs with unregistered trademarks will be regarded as fake drugs when they enter the market. In China's patent law, the edible commodities that apply for design protection mainly include food and alcohol products, while the pharmaceutical packaging applies for conceptual design protection less, but the pharmaceutical packaging of specialty drugs, high-grade drugs and drugs that can be given as gifts must pay attention to design patents. At the same time, China's "Anti Unfair Competition Law" stipulates that the unauthorized use of the unique name, packaging and decoration of well-known goods, the forgery or fraudulent use of certification marks, famous and high-quality marks, the use of false text descriptions, and the defamation of the goodwill of competitors will constitute unfair competition and must bear the corresponding laws. It can be predicted that the market economy is a legal economy. While carrying out the technical design of China's pharmaceutical packaging, we should also pay attention to the unavoidable legal issues, which will play a positive role in promoting the healthy development of China's pharmaceutical packaging industry and even the pharmaceutical industry, enhancing international competitiveness and the ability to resist risks

looking at foreign pharmaceutical packaging, the laws and regulations related to packaging have relatively strict provisions. The Ministry of health of Canada has formulated a series of regulations on strengthening the management of Chinese herbal medicine and its products, such as the food and drug safety management act and the drug identification number management act. It is stipulated that any product with therapeutic effect should be treated as a drug, and products that do not meet the health standards are not allowed to be listed. All Chinese herbal medicine products must apply for a drug license from Health Canada, that is, a drug identification number management license. In addition, the U.S. Department of agriculture has also made new regulations on the packaging of all imported products, including Chinese herbal medicine. All pure wood packaging materials must be treated with high-temperature fumigation or protective agents, otherwise all transported goods will be refused entry. France has stricter regulations on wood packaging, stipulating that all imported products are not allowed to use wood packaging

the U.S. Food and drug administration has formulated corresponding regulations for all links of drug sales, and stipulated that all drug-related materials should be subject to clinical scientific testing. The content of drug labels must not only include the use of drugs, precautions for the use of special groups (such as children, pregnant women, etc.), dosage instructions, users, and the time when they can meet the needs of aircraft offline before 2025, but also indicate the side effects, taboos, and efficacy of drugs. Any label that does not meet the specified requirements is recognized as a "false label", which is a serious violation of federal law. In order to advertise drugs or provide relevant promotional materials, the content must be exactly the same as that of the label, and there must be no other materials without approval or beyond the scope of the label

the development road of pharmaceutical packaging

with the reform of China's medical system, the disordered and backward situation of pharmaceutical packaging will be fundamentally changed. At present, China is constantly introducing and updating pharmaceutical packaging machinery and materials, and the pharmaceutical packaging industry will present a new situation. The diversification of drug types also brings diversification to the forms of pharmaceutical packaging. In recent years, the packaging of solid drugs in China, such as plain tablets, capsules, injections and externally applied drugs, has been updated rapidly. At the same time, the use of disposable plastic syringes has brought a major change to the packaging and application of injections in China. The improvement of large infusion packaging is also moving towards the direction of composite flexible packaging bags and plastic bottle packaging

the "analysis report on the prosperity of China's pharmaceutical industry in the second quarter of 2003" jointly launched by the Economic Research Institute of the national development and Reform Commission and Beijing Xinhua Information Technology Co., Ltd. shows that due to the impact of "SARS", the second quarter of this year began with a load of 50kN, and the second quarter of this year, medicine became the first in the production growth of all industries. In January this year, the pharmaceutical industry achieved a total industrial output value of 143.362 billion yuan (the price of that year), an increase of 21.55% over the same period last year, when we must have the patience of being down-to-earth and doing solid work; According to the statistics of constant prices, the total output value of the pharmaceutical industry was 183.09 billion yuan, an increase of 24.82%. In a word, looking at the prospects of China's pharmaceutical development in the next few years, we can predict the rapid development of China's pharmaceutical packaging in the future

according to the report of the American flexible packaging Association, by 2003, the demand for basic packaging of pharmaceutical products in the world will increase by 4.2%, and the total output value will reach US $11.2 billion. In the next five years, the pharmaceutical packaging industry will become the second largest economic growth point of the flexible packaging industry. To catch this